ストックスクリーナーアプリを入手
6.40
0.85%
-0.055
アフターアワーズ：
6.39
-0.01
-0.16%
前日終値:
$6.455
開ける：
$6.36
24時間の取引高:
24,022
Relative Volume:
0.26
時価総額：
$245.99M
収益：
$4.71M
当期純損益:
$-46.77M
株価収益率:
-3.8113
EPS:
-1.6792
ネットキャッシュフロー:
$-60.34M
1週間 パフォーマンス:
+2.07%
1か月 パフォーマンス:
-15.57%
6か月 パフォーマンス:
-35.44%
1年 パフォーマンス:
-22.89%
1日の値動き範囲:
$6.2501
$6.47
1週間の範囲:
$6.02
$6.60
52週間の値動き範囲:
$5.55
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
NYXH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
6.40 | 245.99M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
474.26 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
194.07 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
81.45 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
285.17 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
244.50 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-31 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-19 | 開始されました | Robert W. Baird | Neutral |
| 2022-04-21 | 開始されました | Oppenheimer | Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Peer Perform |
| 2021-12-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Nyxoah Sa (NYXH) 最新ニュース
Nyxoah sees Q2 revenue up 73%, plans R&D shift to U.S. and Belgium; shares rise - MSN
Price Channel Expanding on Nyxoah SA’s Chart2025 EndofYear Setup & AI Powered Market Entry Strategies - classian.co.kr
Nyxoah: The High-Risk High-Reward Medtech To Own (NASDAQ:NYXH) - Seeking Alpha
Brainstorm Posts 43% EPS Gain in Q2 - AOL.com
Oncology Institute Sales Jump 22 Percent - AOL.com
Vivos Therapeutics Unveils New Model - AOL.com
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift - AOL.com
UroGen (URGN) Q2 Revenue Rises 11% - AOL.com
Nyxoah total operating loss for Q2 2025 hits €19.9M - Medical Buyer
Oppenheimer reiterates Outperform rating on Nyxoah stock with $13 target - Investing.com
Stifel reiterates Buy rating on Nyxoah stock following FDA approval - Investing.com
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - AOL.com
Nyxoah’s Genio System Gains FDA Approval - TipRanks
Nyxoah's FDA Approval and U.S. Launch of Genio System: A High-Conviction Play in the OSA Market? - AInvest
Earnings call transcript: Nyxoah Q2 2025 sees stock rise post-earnings By Investing.com - Investing.com Nigeria
Nyxoah Q2 Revenue Jumps 74 Percent - AOL.com
NeuroPace Revenue Jumps 22 Percent in Q2 - AOL.com
Nyxoah's Q2 2025: Unpacking Key Contradictions in Commercial Launch, Reimbursement, and Regulatory Strategies - AInvest
Earnings call transcript: Nyxoah Q2 2025 sees stock rise post-earnings - Investing.com
Nyxoah (NYXH) Q2 2025 Earnings Call Transcript - Mitrade
Nyxoah Q2 2025 Earnings Call Transcript - MarketBeat
Nyxoah Q2 Revenue Jumps 74 Percent - The Motley Fool
Nyxoah Launches Genio System in U.S. Following FDA Approval - TipRanks
Nyxoah SA reports results for the quarter ended June 30Earnings Summary - TradingView
Nyxoah Reports Second Quarter Financial and Operating Results - The Manila Times
First-Ever Bilateral Sleep Apnea Neurostimulation Device: Nyxoah's Genio Gets FDA Green Light with 67% Efficacy - Stock Titan
Nyxoah : Q2 Report 2025 - MarketScreener
Can Traders Expect Breakout From Nyxoah SA This WeekJuly 2025 Market Mood & Weekly Top Gainers Alerts - newsimpact.co.kr
Market reaction to Nyxoah SA’s recent newsBond Market & Capital Efficiency Focused Ideas - Newser
Visualizing Nyxoah SA stock with heatmapsQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Will Nyxoah SA benefit from macro trendsPortfolio Update Summary & Risk Managed Trade Strategies - Newser
How to read the order book for Nyxoah SAPortfolio Gains Report & Verified Stock Trade Ideas - Newser
Will Nyxoah SA be affected by tariffsTrade Signal Summary & Technical Analysis for Trade Confirmation - mustnews.co.kr
Nyxoah SA stock momentum explained2025 Price Momentum & Weekly High Potential Alerts - Newser
Using data filters to optimize entry into Nyxoah SA2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Will Nyxoah SA announce a stock splitJuly 2025 Technicals & AI Enhanced Market Trend Forecasts - thegnnews.com
Smart tools for monitoring Nyxoah SA’s price actionTrade Exit Summary & Expert Curated Trade Ideas - Newser
Adagio Medical Posts Narrower Q2 Loss - AOL.com
Is Nyxoah SA forming a reversal patternWeekly Gains Report & Smart Swing Trading Techniques - Newser
Nyxoah Secures FDA Approval for Innovative Sleep Apnea Treatment - AInvest
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea - Yahoo Finance
What drives Nyxoah SA’s stock priceQuarterly Trade Report & Verified Short-Term Plans - mustnews.co.kr
Nyxoah SA Uptrend in Early Stages Indicators Say YesWeekly Profit Recap & Real-Time Volume Triggers - newsyoung.net
What’s the recovery path for long term holders of Nyxoah SAQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Top chart patterns to watch in Nyxoah SAEarnings Risk Report & Detailed Earnings Play Alerts - Newser
Verrica Posts Profit in Fiscal Q2 - AOL.com
Adaptimmune Sales Jump 59 Percent - AOL.com
Citius Oncology Beats Fiscal Q3 EPS - AOL.com
When is the best time to buy Nyxoah SA stockWeekly Trade Review & Reliable Trade Execution Plans - Newser
Nyxoah wins FDA approval for Genio OSA treatment - BioWorld MedTech
Nyxoah Gains FDA Approval for Genio System, Reports 73% Revenue Increase in Q2 2025. - AInvest
Nyxoah Sa (NYXH) 財務データ
収益
当期純利益
現金流量
EPS
2.19%
0.26%
大文字化:
|
ボリューム (24 時間):